Posts tagged Innovationspotlight
From London to Silicon Valley and back again: A scientific entrepreneur’s tale

I visited Sixfold Biosciences in the Imperial College Innovation and Translation Hub to have a chat with their co-founder Anna Perdrix Rosell. Anna is an oncology PhD student at the Francis Crick Institute and made it onto the Forbes 30 under 30 list for European science and healthcare this year. With her co-founders, George Foot and Zuzanna Brzosko, they are developing Sixfold’s unique Programmable Oligonucleotide Delivery Devices (PODDs), which aim to deliver gene therapy molecules exclusively to diseased cells. Sixfold Bioscience went through Y Combinator (the top U.S. accelerator) at the beginning of 2018 and have since received seed funding from Silicon Valley investors. We discussed what it was like starting a company during her PhD, the key barriers facing young entrepreneurial scientists and what motivated her to work in biotech.

Read More
The Magnificent Seven Life Science Startups Hitting London this Summer

Exciting life sciences startups from around the world are kicking off their acceleration in London
this week. RebelBio, the world’s first life sciences accelerator and owned by SOSV, has taken
on seven companies for Cohort VI and they are working on some extremely innovative and
disruptive tech. Whether you are into sustainability in the food sector, artificial intelligence and
machine learning, neurodegenerative disease or the microbiome (to name a few) there is
something here that you’ll want to follow. These companies include science lovers from a range
of backgrounds, including BScs, MBAs, PhDs, doctors, surgeons, CEOs and visionaries, who
are being thrust into a full-on three month programme including investment, mentorship and
business training with RebelBio.

Read More
A startup from London brings personalised epigenetic testing directly to the everyday consumer.

As part of this month’s #genomejuly topic I was interested in the advances of the epigenome innovations in the biotech industry. I, therefore, recently spoke with Chronomics CEO, Dr. Tom Stubbs. Chronomics is a startup that brings personalised epigenetic testing directly to the everyday consumer. They offer a saliva test that will enable you to track epigenetic changes as a consequence of your diet, environment and lifestyle. Epigenetics is the study of alterations in the expression of genes without direct changes to the genetic code itself. During this month’s interview we spoke about Chronomics’ development and their realization in of the potential of epigenetic testing for personal health. I discussed with Tom the key challenges Chronomics overcame in their growth as an early-stage biotech company and his advice to aspiring entrepreneurs in the life sciences.

Read More
The entrepreneurial journey of Timothy Brownstone (CEO of KYMIRA Sport)

The idea was initially developed by its CEO Timothy Brownstone, who had previously read a NASA research paper whilst at university discussing how infrared could be used to aid the growth of plants in space. With the understanding of this infrared technology, Tim set out to develop the concept of KYMIRA Sport which embeds Far Infrared (FIR) producing technology into the fabric of its sports clothing products. The technology in the fabric enhances the user’s performance and recovery during intense training and exercise by absorbing the waste energy from the body and latent energy from the environment. This energy is converted into FIR which increases the production of nitric oxide which then leads to increases in circulation, tissue oxygenation, energy production, pain relief and an increased efficiency in respiration.

Read More
Open Cell is transforming shipping containers into lab space in London

Looking for affordable office and lab space in London? - Join Open Cell

Join an exciting pool of talented scientists, designers and early-stage businesses in Shepherd's Bush Open Cell bio-space. Open Cell contains 20 containers for early-stage startups, 10 studio spaces and 10 fully equipped labs. The Open Cell aims to provide affordable lab and office space to create and foster an innovation-driven environment for the next generation of scientist-entrepreneurs.

Read More
Innovation in the human microbiome

The human body contains trillions of micro-organisms, with an estimated 3.8∙10^13 bacterial cells accounting for up to 0.2 kg of body weight (Sender, R. et al., 2016). These microbes live within us in a symbiotic relationship and research has led to the understanding that they prove vital to our physiological functions. As vital as they are in remaining healthy, they are highly associated with causing or contributing to the development of many chronic diseases. These microbes are collectively known as ‘the human microbiota’ and the ‘microbiome’ is the term which describes the genes of all these microbes. The microbiome is unique to every individual and the extent to which it affects vital bodily functions is only just beginning to be really understood.

Read More
RebelBio partners with Clustermarket to support startups with state-of-the-art resources.

London, United Kingdom -- Clustermarket, the online sharing platform helping scientists, engineers and other technology pioneers to get easy and affordable access to equipment and services just announced a strategic partnership with RebelBio, the world's first early-stage life sciences accelerator with programmes in London and Cork. Clustermarket is providing companies backed by RebelBio access to the resources they need on demand with exclusive offers.

Read More
UK’s first online marketplace for scientists breaks down barriers to entry for life science start-ups

For the first time , companies and scientists will be able to book expertise, lab space and equipment outside their institution via an online platform, creating a new dawn for independent life science research in the UK.

Clustermarket (www.clustermarket.com) has launched in partnership with Merck Accelerator as the UK’s first online marketplace for scientists – enabling grassroots scientific research and ‘access for all’ in life sciences.

Read More